Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy [0.03%]
意大利类风湿关节炎患者使用阿巴西普的基于试验的成本效益分析
J Gaultney,M Benucci,S Iannazzo et al.
J Gaultney et al.
Introduction: Rheumatoid arthritis (RA) is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment is a significant economic burden on the Italian healthcare system. Economi...
Randomized Controlled Trial
Expert review of pharmacoeconomics & outcomes research. 2016 Jun;16(3):409-17. DOI:10.1586/14737167.2016.1102636 2016
Prevalence, awareness, characteristics, and health outcomes associated with COPD at-risk status among adults in Japan [0.03%]
日本成人慢性阻塞性肺疾病高危状态的流行率、知晓率、特征和健康结果
Hisamitsu Omori,Daisuke Yoshimoto,Maya Kumar et al.
Hisamitsu Omori et al.
Objectives: We examined the prevalence of chronic obstructive pulmonary disease (COPD) diagnosed and at-risk status, and public awareness of COPD among adults in Japan, as well as respondent characteristics and health out...
Prevalence, awareness, and burden of major depressive disorder in urban China [0.03%]
中国城市成人抑郁症的流行病学特征、知晓率及疾病负担
Shaloo Gupta,Amir Goren,Peng Dong et al.
Shaloo Gupta et al.
Objectives: This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. Methods: ...
The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis [0.03%]
乌司奴单抗治疗中至重度银屑病的成本效果分析
Nicole C Rouse,Michael E Farhangian,Brooke Wehausen et al.
Nicole C Rouse et al.
Given its chronicity and impact on quality of life, psoriasis is a costly disease. As new and better treatments are developed, the cost of treating psoriasis has risen. In this drug profile, the authors discuss ustekinumab, its pharmacokine...
Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples [0.03%]
异构配偶之间的艾滋病传播：基于异性恋艾滋病病毒阴阳伴侣研究的系统评价和meta分析
Foteini K Giannou,Chrissa G Tsiara,Georgios K Nikolopoulos et al.
Foteini K Giannou et al.
Objective: This systematic review and meta-analysis aimed to reassess the effectiveness of condoms in reducing heterosexual transmission of HIV. Methods: ...
The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology [0.03%]
延长寿命的治疗手段的经济特点：癌症卫生经济学评价中的费用计算方法综述
Natalia Olchanski,Yue Zhong,Joshua T Cohen et al.
Natalia Olchanski et al.
Published literature lacks consensus, and most guidelines lack definitive recommendations as to whether cost-effectiveness analyses (CEAs) should include all "future" costs or distinguish between related and unrelated medical costs. This sy...
Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature [0.03%]
癌症幸存者随访策略的经济评价：文献的系统综述和质量评估
Michela Meregaglia,John Cairns
Michela Meregaglia
The aim of this study was to review and critically assess the health economics literature on post-treatment follow-up for adult cancer survivors. A systematic search was performed using PubMed, EMBASE and the Cochrane Library. The Consolida...
Usha Sambamoorthi,Xi Tan,Arijita Deb
Usha Sambamoorthi
The prevalence of multiple chronic conditions (MCC) is increasing among individuals of all ages. MCC are associated with poor health outcomes. The presence of MCC has profound healthcare utilization and cost implications for public and priv...
Analytic approaches for research priority-setting: issues, challenges and the way forward [0.03%]
研究优先顺序的制定问题、挑战及未来方向——分析方法展望
Lazaros Andronis
Lazaros Andronis
In the last two decades, growing demand for studies assessing healthcare interventions, coupled with the acknowledgment that limited public funds for research ought to be allocated efficiently, has led to increasing calls for the use of ana...
The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs [0.03%]
韩国新的药品定价政策对上市药品市场竞争的影响分析
Hye-Young Kwon,Hyungmin Kim,Brian Godman et al.
Hye-Young Kwon et al.
Introduction: A new pricing policy was introduced in Korea in April 2012 with the aim of strengthening competition among off-patent drugs by eliminating price gaps between originators and generics. ...